Stockscreener 앱 받기
1.1999
0.42%
-0.0051
시간 외 거래:
1.15
-0.0499
-4.16%
전일 마감가:
$1.205
열려 있는:
$1.23
하루 거래량:
7,920
Relative Volume:
0.12
시가총액:
$2.38M
수익:
-
순이익/손실:
$-9.32M
주가수익비율:
-0.0944
EPS:
-12.7107
순현금흐름:
$-7.30M
1주 성능:
+6.20%
1개월 성능:
-17.82%
6개월 성능:
-38.47%
1년 성능:
-77.85%
1일 변동 폭
$1.19
$1.23
1주일 범위
$1.05
$1.28
52주 변동 폭
$0.952
$6.4485
Tharimmune Inc Stock (THAR) Company Profile
명칭
Tharimmune Inc
전화
302-743-2995
주소
1200 ROUTE 22 EAST, BRIDGEWATER
THAR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.1999 | 2.38M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc 주식(THAR)의 최신 뉴스
Tharimmune announces board retirements ahead of annual meeting By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - standard-journal.com
Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan
Tharimmune reports data on new biparatopic biologics - BioWorld MedTech
THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa
THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia
Tharimmune Reports Preclinical Data for Dual-Target Biologics - MarketScreener
Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology - MarketScreener
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Weatherford Democrat
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition - Stock Titan
Tharimmune receives Nasdaq non-compliance notice - Investing.com Australia
Tharimmune receives Nasdaq non-compliance notice By Investing.com - Investing.com Canada
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update - Defense World
Virtu Financial LLC Makes New Investment in Tharimmune, Inc. (NASDAQ:THAR) - Defense World
THAR stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa
Jayud Global Logistics Ltd (JYD): What Makes The Stock Good? - Marketing Sentinel
THAR stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com
Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure - MarketScreener
FDA greenlights Tharimmune’s drug application pathway - Investing.com India
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Weatherford Democrat
FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat
Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - Stock Titan
Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online
Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider
Tharimmune unveils novel cancer treatment HS1940 - Investing.com India
Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada
Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com
Tharimmune Says Thomas Hess Resigns As CFO - TradingView
Tharimmune appoints new CFO following resignation - Investing.com
Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada
Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com
Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter
Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World
Larchmont broker accused of years-long insider trading scheme - Westfair Communications
Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World
Tharimmune Inc (THAR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tharimmune Inc 주식 (THAR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
0.24%
36.06%
자본화:
|
볼륨(24시간):